Skip to main content
SpringerLink
Log in

The motor effects of bromocriptine — a review

  • Review
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

For many years, bromocriptine has proven to be a useful treatment for some of the disabling motor effects seen in Parkinson's disease. As such, it has been the only commonly used directly acting D2 agonist available. But its mechanism of action has been obscure because many animal models indicated an absolute requirement for the presence of endogenous DA for bromocriptine to have any efficacy, despite its undoubted occupation of the D2 receptor with high affinity. Several scattered reports indicated, however, that bromocriptine could potentiate the effects of a number of other dopamine agonists (such as apomorphine and l-dopa) in a variety of pharmacological models and in the clinic. With the availability of SKF38393 and SCH23390, it soon became clear that bromocriptine, while a selective D2 agonist, depended in an absolute sense on the integrity of the D1 receptors. Thus, if SKF38393 was administered together with bromocriptine to rodents depleted of dopamine, marked locomotor excitation was produced, despite either drug alone being inactive. The present review explores the literature on the motor effects of bromocriptine and endeavours to integrate its behavioural, biochemical and electrophysiological effects into a coherent whole. It closes with a consideration of several remaining unsolved problems associated with the pharmacology of bromocriptine and suggests some future studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aghajanian GK, Bunney BS (1977) Dopamine autoreceptors: pharmacological characterization by microiontophoretic single-cell recording studies. Naunyn-Schmiedeberg's Arch Pharmacol 297:1–7

    Google Scholar 

  • Ahlenius S, Andén N-E, Engel J (1973) Restoration of locomotor activity in mice by low l-DOPA doses after supression by alpha-methyltyrosine but not by reserpine. Brain Res 62:189–199

    Google Scholar 

  • Andén N-E, Strömbom U, Svensson TH (1973) Dopamine and noradrenaline receptor stimulation: reversal of reserpine induced supression of motor activity. Psychopharmacologia 29:289–298

    Google Scholar 

  • Andersen PH, Braestrup C (1986) Evidence for different states of the dopamine D1 receptor: clozapine and fluperlapine may preferentially label an adenylate cyclase-coupled state of the D1 receptor. J Neurochem 47:1822–1831

    Google Scholar 

  • Anlezark G, Pycock C, Meldrum B (1976) Ergot alkaloids as dopamine agonists: comparison in two rodent models. Eur J Pharmacol 37:295–302

    Google Scholar 

  • Arnt J, Hyttel J (1984) Differential inhibition by dopamine D-1 and D-2 antagonists of circling behaviour induced by dopamine agonists in rats with unilateral 6-hydroxydopamine lesions. Eur J Pharmacol 102:349–354

    Google Scholar 

  • Arnt J, Hyttel J, Perregaard J (1987) Dopamine D-1 receptor agonists combined with the selective D-2 agonist quinpirole facilitate the expression of oral stereotyped behaviour in rats. Eur J Pharmacol 133:137–145

    Google Scholar 

  • Bannon MJ, Grace AA, Bunney BS, Roth RH (1980) Evidence for an irreversible interaction of bromocriptine with central dopamine receptors. Naunyn-Schmiedeberg's Arch Pharmacol 312:37–41

    Google Scholar 

  • Barone P, Davis TA, Braun AR, Chase TN (1986) Dopaminergic mechanisms and motor function: characterization of D-1 and D-2 dopamine receptor interactions. Eur J Pharmacol 123:109–114

    Google Scholar 

  • Beart PM, McDonald D, Cincotta M, De Vries DJ, Gundlach AL (1986) Selectivity of some ergot derivatives for 5-HT1 and 5-HT2 receptors of rat cerebral cortex. Gen Pharmacol 17:57–62

    Google Scholar 

  • Braun AR, Chase TN (1986) Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviours. Eur J PHarmacol 131:301–306

    Google Scholar 

  • Braun A, Fabbrini G, Mouradian MM, Serrati C, Barone P, Chase TN (1987) Selective D-1 dopamine receptor agonist treatment of Parkinson's Disease. J Neural Transm 68:41–50

    Google Scholar 

  • Breese GR, Napier TC, Mueller RA (1985) Dopamine agonist induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats. J Pharmacol Exp Ther 234:447–455

    Google Scholar 

  • Bürki HR (1978) Lack of effect of bromocriptine on the activity of monoamine oxidase in rat brain. J Pharm Pharmacol 30:261–262

    Google Scholar 

  • Bürki HR, Asper H, Ruch W, Züger PE (1978) Bromocriptine, dihydroergotoxine, methysergide, d-LSD, CF 25–397 and 29–712: effects on the metabolism of the biogenic amines in the brain of the rat. Psychopharmacology 57:227–237

    Google Scholar 

  • Burt DR, Creese I, Snyder SH (1976) Properties of [3H]haloperidol and [3H]dopamine binding associated with dopamine receptors in calf brain membranes. Mol Pharmacol 12:800–812

    Google Scholar 

  • Calabro MA, MacLeod RM (1978) Binding of dopamine to bovine anterior pituitary gland membranes. Neuroendocrinology 25:32–46

    Google Scholar 

  • Carlsson A (1975) Receptor-mediated control of dopamine metabolism. In: Usdin E, Bunney WE (eds) Pre- and postsynaptic receptors, Dekker, New York

    Google Scholar 

  • Colboc O, Protais P, Costentin J (1983) Pharmacological evidence against the involvement of the D1 subtype of dopamine receptors in apomorphine-induced hypothermia. Neurosci Lett 39:211–216

    Google Scholar 

  • Consolo S, Ladinsky H, Pugnetti P, Fusi R, Crunelli V (1981) Increase in rat striatal acetylcholine content by bromocriptine: evidence for an indirect dopaminergic action. Life Sci 29:457–465

    Google Scholar 

  • Corrodi H, Fuxe K, Hökfelt T, Lidbrink P, Ungerstedt U (1973) Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. J Pharm Pharmacol 25:409–412

    Google Scholar 

  • Corrodi H, Farnebo L-O, Fuxe K, Hamberger B (1975) Effects of ergot drugs on central 5-hydroxytryptamine neurons: evidence for 5-hydroxytryptamine release or 5-hydroxytryptamine receptor stimulation. Eur J Pharmacol 30:172–181

    Google Scholar 

  • Costall B, Lim SK, Naylor RJ (1981) Characterization of the mechanisms by which purported dopamine agonists reduce spontaneous locomotor activity in mice. Eur J Pharmacol 73:175–188

    Google Scholar 

  • Cote TE, Eskay RL, Frey EA, Grewe CW, Munemura M, Tsuruta K, Brown EM, Kebabian JW (1983) Actions of lisuride on adrenoceptors and dopamine receptors. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York; pp 45–53

    Google Scholar 

  • Coward DM, Doggett NS (1977) The production of an alternative laboratory model of the Parkinson syndrome using a new benzylimidoylurea derivative LON 954. Psychopharmacology 52:165–171

    Google Scholar 

  • Creese I, Schneider R, Snyder SH (1977) 3H-Spiroperidol labels dopamine receptors in pituitary and brain. Eur J Pharmacol 46:377–381

    Google Scholar 

  • Creese I, Usdin TB, Snyder SH (1979) Dopamine receptor binding regulated by guanine nucleotides. Mol Pharmacol 16:69–76

    Google Scholar 

  • Creese I, Leff SE, Sibley DR, Hamblin MW (1984) Radioligand binding studies of agonist interactions with dopamine receptors. In: Poste G, Crooke ST (eds) Dopamine receptor agonists. Plenum Press, New York, pp 23–64

    Google Scholar 

  • Di Chiara G, Porceddu ML, Vargui L, Stefanini E, Gessa GL (1977) Evidence for selective and long-lasting stimulation of “regulatory” dopamine-receptors by bromocriptine (CB-154). Naunyn-Schmiedeberg's Arch Pharmacol 300:239–245

    Google Scholar 

  • Dolphin AC, Jenner P, Sawaya MCB, Marsden CD, Testa B (1977) The effect of bromocriptine on locomotor activity and cerebral catecholamines in rodents. J Pharm Pharmacol 29:727–734

    Google Scholar 

  • Dray A, Oakley NR (1976) Bromocriptine and dopamine-receptor stimulation. J Pharm Pharmacol 28:586–588

    Google Scholar 

  • Enjalbert A, Bockaert J (1983) Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary. Mol Pharmacol 23:576–584

    Google Scholar 

  • Fage D, Scatton B (1986) Opposing effects of D-1 and D-2 receptor antagonists on acetylcholine levels in the rat striatum. Eur J Pharmacol 129:359–362

    Google Scholar 

  • Fang VS (1981) Pharmacological difference of l-DOPA, apomorphine, and bromocriptine against metoclopramide. Life Sci 28:2143–2144

    Google Scholar 

  • Fleminger S, Jenner P, Marsden CD, Testa B, van de Waterbeemd H (1983) Selectivity of dopamine agonists at D-1 and D-2 receptors does not depend on lipid solubility. Br J Pharmacol 79:410P

    Google Scholar 

  • Freedman SB, Poat JA, Woodruff GN (1981) [3H]Sulpiride, a ligand for neuroleptic receptors. Neuropharmacology 20:1323–1326

    Google Scholar 

  • Fuller RW, Perry KW (1982) Effect of haloperidol pre- and post-treatment on the ability of pergolide and bromocriptine to antagonise the gamma-butyrolactone-induced increase in brain dopamine in rats. Biochem Pharmacol 31:2199–2200

    Google Scholar 

  • Fuxe K, Fredholm BB, Agnati LF, Ögren S-O, Everitt BJ, Jonsson G, Gustafsson J-Å (1978a) Interaction of ergot drugs with central monoamine systems. Pharmacology [Suppl 1]16:99–134

    Google Scholar 

  • Fuxe K, Fredholm BB, Ögren S-O, Agnati L.F, Hökfelt T, Gustafsson J-Å (1978b) Ergot drugs and central monoaminergic mechanisms: a histochemical, biochemical and behavioural analysis. Fed Proc 37:2181–2191

    Google Scholar 

  • Fuxe K, Fredholm BB, Ögren S-O, Agnati LF, Hökfelt T, Gustafsson J-Å (1978c) Pharmacological and biochemical evidence for the dopamine agonist effect of bromocriptine. Acta Endocrinol 88:27–56

    Google Scholar 

  • Fuxe K, Agnati LF, Köhler C, Kuonen D, Ögren S-O, Andersson K, Hökfelt T (1981) Characterization of normal and supersensitive dopamine receptors: effects of ergot drugs and neuropeptides. J Neural Transm 51:3–37

    Google Scholar 

  • Gmelin GW (1978) Microelectrophoretic studies with 2-bromo-alpha-ergocriptine on dopaminergic neurons in the feline caudate nucleus. Life Sci 23:485–488

    Google Scholar 

  • Goldstein M, Lew JY, Nakamura S, Battista AF, Lieberman A, Fuxe K (1977) Dopaminephilic properties of ergot alkaloids. Fed Proc 37:2202–2206

    Google Scholar 

  • Goldstein M, Lieberman A, Battista AF, Lew JY, Hata F (1978) Bromocriptine, lergotrile: the antiparkinsonian efficacy and the interaction with monoaminergic receptors. Pharmacology [Suppl 1]16:143–149

    Google Scholar 

  • Goldstein M, Lieberman A, Battista AF (1984) The therapeutic potential of centrally acting dopamine agonists. TIPS 5:227–230

    Google Scholar 

  • Goldstein M, Lieberman A, Meller E (1985) A possible molecular mechanism for the antiparkinsonian action of bromocriptine in combination with levodopa. TIPS 6:436–437

    Google Scholar 

  • Gonzalez-Lima F, Hart WT, Rivera-Quinones C (1987) Metabolite involvement in the behavioural effects of bromocriptine in cats. Eur J Pharmacol 141:109–115

    Google Scholar 

  • Gorell JM, Czarnecki B, Hubbell S (1986) Functional antagonism of D-1 and D-2 dopaminergic mechanisms affecting striatal acetylcholine release. Life Sci 38:2247–2254

    Google Scholar 

  • Gundlach AL, Krstich M, Beart PM (1983) Guanine nucleotides reveal differential actions of ergot derivatives at D-2 receptors labelled by [3H]spiperone in striatal homogenates. Brain Res 278:155–163

    Google Scholar 

  • Hallett M (1981) Bromocriptine for levodopa-induced end-of-dose dystonia. Lancet I:616

    Google Scholar 

  • Heal DJ, Green AR (1978) Repeated electroconvulsive shock increases the behavioural responses of rats to injection of both dopamine and dibutyryl cyclic AMP into the nucleus accumbens. Neuropharmacology 17:1085–1087

    Google Scholar 

  • Heal DJ, Green AR, Buylaert WA (1980) Inhibition of apomorphine-, bromocriptine-, and lergotrile-induced circling behaviour in rats by subsequent haloperidol administration. Neuropharmacology 19:133–137

    Google Scholar 

  • Herndon H, Strupish J, Nahorski SR (1987) Endogenous dopamine release from rat striatal slices and its regulation by D-2 autoreceptors: effects of uptake inhibitors and synthesis inhibition. Eur J Pharmacol 138:69–76

    Google Scholar 

  • Hoffmann IS, Cubeddu LX (1984) Differential effects of bromocriptine on dopamine and acetylcholine release modulatory receptors. J Neurochem 42:278–282

    Google Scholar 

  • Horowski R (1978) Differences in the dopaminergic effects of the ergot derivatives bromocriptine, lisuride, and d-LSD as compared with apomorphine. Eur J Pharmacol 51:157–166

    Google Scholar 

  • Hruska RE, Silbergeld E (1981) Inhibition of neurotransmitter receptor binding by ergot derivatives. J Neurosci Res 6:1–11

    Google Scholar 

  • Hyttel J (1983) SCH 23390 — The first selective dopamine D-1 antagonist. Eur J Pharmacol 91:153–154

    Google Scholar 

  • Iorio LC, Barnett A, Leitz H, Houser VP, Korduba CA (1983) SCH 23390, a potential benazepine antipsychotic with unique interactions on dopaminergic systems. J Pharmacol Exp Ther 226:462–468

    Google Scholar 

  • Jackson DM, Hashizume M (1986) Bromocriptine induces marked locomotor stimulation in dopamine-depleted mice when D-1 dopamine receptors are stimulated with SKF38393. Psychopharmacology 90:147–149

    Google Scholar 

  • Jackson DM, Hashizume M (1987) Bromocriptine-induced locomotor stimulation in mice is modulated by dopamine D-1 receptors. J Neural Transm 69:131–145

    Google Scholar 

  • Jackson DM, Jenkins OF (1985) Hypothesis: Bromocriptine lacks intrinsic dopamine receptor stimulating properties. J Neural Transm 62:219–230

    Google Scholar 

  • Jackson DM, Andén N-E, Dahlström A (1975) A functional effect of dopamine in the nucleus accumbens and in some other dopamine-rich parts of the rat brain. Psychopharmacology 45:139–149

    Google Scholar 

  • Jackson DM, Dreher K, Ross SB (1987) D1 and D2 dopamine agonist synergism and the nucleus accumbens. TIPS 8:419–420

    Google Scholar 

  • Jackson DM, Ross SB, Hashizume M (1988a) Further studies on the interaction between bromocriptine and SKF38393 in mice with normosensitive or supersensitive dopamine receptors. Psychopharmacology 94:321–327

    Google Scholar 

  • Jackson DM, Ross SB, Hashizume, M (1988b) Dopamine-mediated behaviours produced in naive mice by bromocriptine plus SKF38393. J Pharm Pharmacol (in press)

  • Jenkins OF, Jackson DM (1985) Bromocriptine potentiates the behavioural effects of directly and indirectly acting dopamine receptor agonists in mice. Naunyn-Schmiedeberg's Arch Pharmacol 331:7–11

    Google Scholar 

  • Jenkins OF, Jackson DM (1986) Bromocriptine enhances the behavioural effects of apomorphine and dopamine after systemic or intracerebral injection in rats. Neuropharmacology 25:1243–1249

    Google Scholar 

  • Jenner P, Rose S, Boyce S, Kelly E, Kilpatrick G, Rupniak NMJ, Briggs R, Marsden CD (1986) Induction of Parkinsonism in the common marmoset by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. In: Fahn S, Marsden CD, Jenner, P Teychenne P (eds) Recent developments in Parkinson's disease. Raven Press, New York, pp 137–146

    Google Scholar 

  • Johnson AM, Loew DM, Vigouret J-M (1976) Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and l-DOPA. Br J Pharmacol 56:59–68

    Google Scholar 

  • Kartzinel R, Perlow M, Teychenne P, Gielen AC, Gillespie MM, Sadawsky DA, Calne DB (1976) Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Lancet II:272–275

    Google Scholar 

  • Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277:93–96

    Google Scholar 

  • Kehr W, Carlsson A, Lindqvist M (1975) Biochemical aspects of dopamine agonists. Adv Neurol 9:185–195

    Google Scholar 

  • Kehr W, Neumeister R, Zimmermann R (1979) Action of ergot derivatives on monoamine synthesis in rat brain. In: Fuxe K, Calne DB (eds) Dopaminergic ergot derivatives and motor function. Pergamon Press, Oxford, pp 173–186

    Google Scholar 

  • Keller HH, Da Prada M (1979) Central dopamine agonistic activity and microsomal biotransformation of lisuride, lergotrile and bromocriptine. Life Sci 24:1211–1222

    Google Scholar 

  • Kelly PH, Moore KE (1976) Mesolimbic dopaminergic neurones in the rotational model of nigrostriatal activity. Nature 263:695–696

    Google Scholar 

  • Kiraly I, Van Ree JM (1984) Non-opiate beta-endorphin fragments and dopamine. VI. Behavioural analysis of the interaction between gamma-type endorphins and dopaminergic systems in the nucleus accumbens of rats. Neuropharmacology 23:511–516

    Google Scholar 

  • Köhler C, Fuxe K, Ögren S-O. Agnati L (1979) Evidence for in vivo binding of apomorphine and bromocriptine to receptor sites not labelled by 3H-spiperone. Eur J Pharmacol 58:339–340

    Google Scholar 

  • Köhler C, Fuxe K, Ross SB (1981) Regional in vivo binding of [3H]N-propyl-apomorphine in the mouse brain. Evidence for labelling of central dopamine receptors. Eur J Pharmacol 72:397–402

    Google Scholar 

  • Köhler C, Hall H, Ögren S-O, Gawell L (1985) Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 34:2251–2259

    Google Scholar 

  • Leff SE, Creese I (1985) Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Mol Pharmacol 27:184–192

    Google Scholar 

  • Lehmann J, Briley M, Langer SZ (1983) Characterization of dopamine autoreceptor and [3H]spiperone binding sites in vitro with classical and novel dopamine receptor agonists. Eur J Pharmacol 88:11–26

    Google Scholar 

  • Lew JY, Hata F, Ohashi T, Goldstein M (1977) The interactions of bromocriptine and lergotrile with dopamine and alpha-adrenergic receptors. J Neural Transm 41:109–121

    Google Scholar 

  • Lieberman A, Zolfaghari M, Boal D, Hassouri H, Vogel B, Battista A, Fuxe K, Goldstein M (1976) The antiparkinson efficacy of bromocriptine. Neurology 26:405–409

    Google Scholar 

  • Loew DM, Vigouret J-M, Jaton AL (1976) Neuropharmacological investigations with two ergot alkaloids, Hydergine and bromocriptine. Postgrad Med J [Suppl 1]52:40–46

    Google Scholar 

  • Loew DM, Vigouret J-M, Jaton AL (1979) Neuropharmacology of ergot derivatives. In: Fuxe K, Calne DB (eds) Dopaminergic ergot derivatives and motor function. Pergamon Press, Oxford, pp 129–140

    Google Scholar 

  • Marek KL, Roth RH (1980) Ergot alkaloids: interaction with presynaptic dopamine receptors in the neostriatum and olfactory tubercules. Eur J Pharmacol 62:137–146

    Google Scholar 

  • Markstein R (1981) Neurochemical effects of some ergot derivatives: a basis for their antiparkinson actions. J Neural Transm 51:39–59

    Google Scholar 

  • Markstein R, Seiler MP, Vigouret JM, Urwyler S, Enz A, Dixon K (1988) Pharmacological properties of CY208-243, a novel D-1 agonist. Proceedings of the VI International Congress of Catecholamines (Jerusalem, 1987), Part B (ed. M. Sandler) (in press)

  • Marsden CD, Jenner P, Parkes JD, Price PA, Reavill C (1979) Dose-dependent locomotor effects of bromocriptine in animals and man — are some of its actions due to metabolites? In: Fuxe Keds, Calne DB Dopaminergic ergot derivatives and motor function. Pergamon Press, Oxford, pp 313–318

    Google Scholar 

  • Martin GE, Williams M, Haubrich DR (1982) A pharmacological comparison of 6,7-dihydroxy-2-dimethylaminotetralin (TL-99) and N-n-propyl-3-(3-hydroxyphenyl)piperidine (3-PPP) with selected dopamine agonists. J Pharmacol Exp Ther 223:298–304

    Google Scholar 

  • Mashurano M, Waddington JL (1986) Stereotyped behaviour in response to the selective D-2 dopamine receptor agonist RU 24213 is enhanced by pretreatment with the selective D-1 agonist SK &F 38393. Neuropharmacology 25:947–949

    Google Scholar 

  • McPherson GA, Beart PM (1983) The selectivity of some ergot derivatives for alpha 1- and alpha 2-adrenoceptors of rat cerebral cortex. Eur J Pharmacol 91:363–369

    Google Scholar 

  • Miller RJ, Kelly PH (1975) Dopamine-like effects of cholera toxin in the central nervous system. Nature 255:163–166

    Google Scholar 

  • Morelli M, Di Chiara G (1985) Catalepsy induced by SCH23390 in rats. Eur J Pharmacol 117:179–185

    Google Scholar 

  • Napier TC, Givens BS, Schulz DW, Bunney BS, Breese GR, Mailman RB (1986) SCH23390 effects on apomorphine-induced responses of nigral dopaminergic neurons. J Pharmacol Exp Ther 236:838–845

    Google Scholar 

  • Narabayashi H, Hondo T, Nagatsu T (1982) l-Threo-3,4-dihydroxyphenylserine treatment for freezing and akinesia in parkinsonism. Neurology 32:A180

  • Ohno Y, Sasa M, Takaori S (1986) Excitation by dopamine D-2 receptor agonists, bromocriptine and LY 171555, in caudate nucleus neurons activated by nigral stimulation. Life Sci 38:1867–1873

    Google Scholar 

  • Pagnini G, Camanni F, Crispino A, Portaleone P (1978) Effects of bromocriptine on adenylate cyclase and phosphodiesterase activities of rat striatum. J Pharm Pharmacol 30:92–95

    Google Scholar 

  • Pijnenburg AJJ, van Rossum JM (1973) Stimulation of locomotor activity following injection of dopamine into the nucleus accumbens. J Pharm Pharmacol 25:1003–1005

    Google Scholar 

  • Pijnenburg AJJ, Woodruff GN, van Rossum JM (1973) Ergometrine induced locomotor activity following intracerebral injection into the nucleus accumbens. Brain Res 59:289–303

    Google Scholar 

  • Pijnenburg AJJ, Honig WMM, Struyker Boudier HAJ, Cools AR, van der Heyden JAM, van Rossum JM (1976a) Further investigations on the effects of ergometrine and other ergot derivatives following injection into the nucleus accumbens of the rat. Arch Int Pharmacodyn Ther 222:103–115

    Google Scholar 

  • Pijnenburg AJJ, Honig WMM, van der Heyden JAM, van Rossum JAM (1976b) Effects of chemical stimulation of the mesolimbic dopamine system upon locomotor activity. Eur J Pharmacol 35:45–58

    Google Scholar 

  • Puech AJ, Simon P, Chermat R, Boissier J-R (1977) Bromocriptin and methylergometrine: pharmacological approach of the mechanism of their central effects. Pharmacol Res Commun 9:299–306

    Google Scholar 

  • Quik M, Iversen LL (1978) Subsensitivity of the rat striatal dopaminergic system after treatment with bromocriptine: effects on [3H]spiperone binding and dopamine-stimulated cyclic AMP formation. Naunyn-Schmiedeberg's Arch Pharmacol 304:141–145

    Google Scholar 

  • Reavill C, Jenner P, Marsden CD (1980) Metabolite involvement in bromocriptine-induced circling behaviour in rodents. J Pharm Pharmacol 32:278–284

    Google Scholar 

  • Robertson HA (1980) Stimulation of 3H-apomorphine binding by dopamine and bromocriptine. Eur J Pharmacol 61:209–211

    Google Scholar 

  • Robertson GS, Robertson HA (1986) Synergistic effect of D1 and D2 dopamine agonists on turning behaviour in rats. Brain Res 384:387–390

    Google Scholar 

  • Robertson GS, Robertson HA (1987) D1 and D2 dopamine agonist synergism: separate sites of action? TIPS 8:295–299

    Google Scholar 

  • Roehrich H, Dackis CA, Gold MS (1987) Bromocriptine. Med Res Rev 7:243–269

    Google Scholar 

  • Saiani L, Trabucchi M, Tonon GC, Spano PF (1979) Bromocriptine and lisuride stimulate the accumulation of cyclic AMP in intact slices but not in homogenates of rat neostriatum. Neurosci Lett 14:31–36

    Google Scholar 

  • Saller CF, Salama AI (1986) D-1 and D-2 dopamine receptor blockade: interactive effects in vitro and in vivo. J Pharmacol Exp Ther 236:714–720

    Google Scholar 

  • Sawaya MCB, Dolphin A, Jenner P, Marsden CD, Meldrum BS (1977) Noradrenaline-sensitive adenylate cyclase in slices of mouse limbic forebrain: characterization and effect of dopaminergic agonists. Biochem Pharmacol 26:1877–1884

    Google Scholar 

  • Scarnati E, Forchetti C, Ciancarelli G, Pacitti C, Agnoli A (1980) Dopaminergic and non-dopaminergic neurons in substantia nigra: differential response to bromocriptine. J Neural Transm 48:297–303

    Google Scholar 

  • Scatton B (1982) Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: evidence against dopamine receptor multiplicity. J. Pharmacol Exp Ther 220:197–202

    Google Scholar 

  • Schnieden H, Cox B (1976) A comparison between amantadine and bromocriptine using the stereotyped behaviour response test (SBR) in the rat. Eur J Pharmacol 39:133–141

    Google Scholar 

  • Schorderet M (1976) Direct evidence for the stimulation of rabbit retina dopamine receptors by ergot alkaloids. Neurosci Lett 2:87–91

    Google Scholar 

  • Schwarcz R, Fuxe K, Agnati LF, Gustafsson J-A (1978) Effects of bromocriptine on 3H-spiroperidol binding sites in rat striatum. Evidence for actions on dopamine receptors not linked to adenylate cyclase. Life Sci 23:465–470

    Google Scholar 

  • Sethy VH (1979) Regulation of striatal acetylcholine concentration by D2 dopamine receptors. Eur J Pharmacol 60:397–398

    Google Scholar 

  • Setler PE, Sarau HM, Zirkle CL, Saunders HL (1978) The central effects of a novel dopamine agonist. Eur J Pharmacol 50:419–430

    Google Scholar 

  • Sibley DR, Creese I (1983) Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors. Mol Pharmacol 23:585–593

    Google Scholar 

  • Silbergeld EK, Pfeiffer RF (1977) Differential effects of three dopaminergic agonists: apomorphine, bromocriptine and lergotrile. J Neurochem 28:1323–1326

    Google Scholar 

  • Silbergeld EK, Hruska RE (1979) Effects of ergot drugs on serotonergic function: behaviour and neurochemistry. Eur J Pharmacol 58:1–10

    Google Scholar 

  • Silbergeld EK, Adler H, Kennedy S, Calne DB (1977) The roles of presynaptic function and hepatic drug metabolism in the hypothermic actions of two novel dopaminergic agonists. J Pharm Pharmacol 29:632–635

    Google Scholar 

  • Silbergeld EK, Hruska RE, Weir R, Kennedy SW (1979) Dopaminergic and serotonergic effects of ergot drugs. In: Fuxe K, Calne DB (eds) Dopaminergic ergot derivatives and motor function. Pergamon Press, Oxford, pp 223–235

    Google Scholar 

  • Snider SR, Hutt C, Stein B, Prasad ALN, Fahn S (1976) Correlation of behavioural inhibition or excitation produced by bromocriptine with changes in brain catecholamine turnover. J Pharm Pharmacol 28:563–566

    Google Scholar 

  • Starke K, Spath L, Lang JD, Adelung C (1983) Further functional in vitro comparison of pre- and postsynaptic dopamine receptors in the rabbit caudate nucleus. Naunyn-Schmiedeberg's Arch Pharmacol 323:298–306

    Google Scholar 

  • Suchy I, Schneider HH, Riederer P, Horowski R (1983) Considerations on the relevance of differences in receptor affinity of various dopaminergic ergot alkaloids. Psychopharmacol Bull 19:743–746

    Google Scholar 

  • Tissari AH, Lilgälls MS (1988) Modulation of the sensitivity of synaptosomal dopamine autoreceptors to bromocriptine by in vitro and in vivo treatments. In: Beart PM, Woodruff GN, Jackson DM (eds) Pharmacology and functional regulation of dopaminergic neurons. MacMillan Press, London, pp 194–196

    Google Scholar 

  • Titeler M, Seeman P (1980) Ergot and catecholamine potencies at catecholamine receptors. Adv Biochem Psychopharmacol 23:35–40

    Google Scholar 

  • Trabucchi M, Hofmann M, Montefusco O, Spano PF (1978) Ergot alkaloids and cyclic nucleotides in the CNS. Pharmacology [Suppl 1]16:150–155

    Google Scholar 

  • Tsuruta K, Frey EA, Grewe CW, Cote TE, Eskay RL, Kebabian JW (1981) Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor. Nature 292:463–465

    Google Scholar 

  • U'Prichard DC, Greenberg DA, Snyder SH (1977) Binding characteristics of a radiolabelled agonist and antagonist at central nervous system alpha noradrenergic receptors. Mol Pharmacol 13:454–473

    Google Scholar 

  • Ungerstedt U (1971) Post-synaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiol Scand [Suppl 367]82:69–93

    Google Scholar 

  • Wachtel H (1978) Inhibition of locomotor activity of rats by low doses of different dopamine (DA) receptor agonists. Naunyn-Schmiedeberg's Arch Pharmacol [Suppl]302:R59

  • Wang RY (1981a) Dopaminergic neurons in the rat ventral tegmental area. I. Identification and characterization. Brain Res Rev 3:123–140

    Google Scholar 

  • Wang RY (1981b) Dopaminergic neurons in the rat ventral tegmental area. II. Evidence for autoregulation. Brain Res Rev 3:141–152

    Google Scholar 

  • Weick BG, Walters JR (1987a) Effects of D-1 and D-2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D-1/D-2 co-activation induces potentiated responses. Brain Res 405:234–246

    Google Scholar 

  • Weick BG, Walters JR (1987b) D-1 dopamine receptor stimulation potentiates neurophysiological effects of bromocriptine in rats with lesions of the nigrostriatal dopamine pathway. Neuropharmacology 26:641–644

    Google Scholar 

  • Weir RL, Hruska RE, Silbergeld EK (1981) Binding of antiparkinson ergot derivatives to the dopamine receptor. Psychopharmacology 75:119–123

    Google Scholar 

  • White FJ, Wang RY (1984) Pharmacological characterization of dopamine autoreceptors in the rat ventral tegmental area: microiontophoretic studies. J Pharmacol Exp Ther 231:275–280

    Google Scholar 

  • Woolf PD (1981) Resumption of prolactin secretion after dopaminergic inhibition: differential effects of dopamine and its agonists. Am J Physiol 240:E700-E704

    Google Scholar 

Download references

Author information

Author notes

  1. Svante B. Ross

    Present address: Research Laboratories, Astra Alab AB, Södertälje, Sweden

Authors and Affiliations

  1. Department of Pharmacology, The University of Sydney, 2006, New South Wales, Australia

    David M. Jackson, Owen F. Jenkins & Svante B. Ross

Authors
  1. David M. Jackson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Owen F. Jenkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Svante B. Ross
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jackson, D.M., Jenkins, O.F. & Ross, S.B. The motor effects of bromocriptine — a review. Psychopharmacology 95, 433–446 (1988). https://doi.org/10.1007/BF00172952

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00172952

Keywords

Search

Navigation